Navigation Links
China Shenghuo Announces Restated Results For Full Year 2007 & First Quarter 2008, Reports Results For Second & Third Quarter 2008
Date:11/20/2008

2,297 15,923,212 7,894,531 Income (Loss) from Operations 432,408 1,269,738 (1,625,509) 3,228,670 Other Income (Expense): Interest income 588 5,446 5,701 14,712 Income from research and development activities 5,745 384 344,370 81,388 Interest expense (272,002) (275,514) (963,198) (665,155) Non-operating expenses (330) -- (138,812) -- Net Other Expense (265,999) (269,684) (751,939) (569,055) Income (Loss) Before Income Taxes 166,409 1,000,054 (2,377,448) 2,659,615 Benefit from (provision for) income taxes (4,471) (86,861) (4,484) 1,223,386 Minority interest in income of subsidiaries (7,652) (45,552) 146,089 (224,348) Net Income (Loss) $154,286 $867,641 $(2,235,843) $3,658,653 Foreign currency translation adjustment 54,116 174,392 744,189 449,189 Comprehensive Income (Loss) $208,402 $1,042,033 $(1,491,654) $4,107,842 Earnings (Loss) Per Share Basic $0.01 $0.04 $(0.11) $0.19 Diluted $0.01 $0.04 $(0.11) $0.19 Weighted-Average Shares Outstanding Basic 19,679,400 19,579,400 19,679,400 19,292,953 Diluted 19,679,400 19,635,898 19,679,400 19,345,401 For more information, please contact: China Shenghuo Pharmaceutical Holdings, Inc. Mr. Changhua Mu Securities Affairs Representative Tel: +86-871-7282698 Email: c.mu@chinashenghuo.net Grayling Global Eddie Cheung Investor Relations Tel: 646-284-9414 Email: '/>"/>
SOURCE China Shenghuo Pharmaceutical Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. ChinaBio(R) Inaugural Partnering Forum Scheduled for June 2009 in Shanghai, China
2. China Documents First Case of Tick-Borne Disease Spread
3. Drug Information Association (DIA) Opens New Office In China
4. China Healthcare Acquisition Corp Agrees to Terminate Agreement to Acquire Europe Asia Huadu Environment Holding Pte, Ltd.
5. China Information Security Technology, Inc. Issues Guidance & Discuss Outlook for 2009
6. China Bio-Immunity Corporation to Report Third Quarter 2008 Financial Results
7. Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC
8. Measles Initiative Supports Disease Prevention for Children in Chinas Earthquake Zone
9. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
10. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
11. China Pharma Holdings, Inc. to Host Third Quarter 2008 Earnings Conference Call at 10 a.m. EST Friday November 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 2RecoverCare Announces the Relocation of Corporate Headquarters to Louisville 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Skincare Industry Newcomer Shines 51058 1Skincare Industry Newcomer Shines 51058 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 1For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 2For Treatment of Dyslipidemia Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials 51055 3Allied World Schedules Second Quarter 2009 Earnings Announcement and Conference Call 51052 1